MGX: Metagenomi, Inc Total Debt to Capital

Corporate company logo of Metagenomi Inc. (MGX)

Metagenomi, Inc. (MGX) delegates laboratory research and drug production to external contractors, maintaining a critical dependence on partner capacities. This chart of the current share price reflects a total debt-to-equity ratio of 0.36. High authority among scientists and support from pharma behemoths enable the company to develop precision genome editing for the therapy of severe pathologies.

metagenomi.co (MGX): Total Debt to Equity Ratio from 02/21/2024 to 10/31/2026

Financial and market metric breakdowns for Metagenomi Therapeutics (MGX)

- price and consensus price forecast:
Price Chart Metagenomi|MGX - Broker Consensus Forecast
- market capitalization information:
Market Capitalization Metagenomi|MGX - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Metagenomi|MGX - Company Net Assets|Market Capitalization to Book Value Ratio metagenomi.co|MGX - Company Assets
- debt and liquidity details:
Total Debt to Equity Ratio Metagenomi, Inc.|MGX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Metagenomi, Inc.|MGX - Company Aggregate Debts|Debts to Book Capitalization Metagenomi|MGX - Long-Term Indebtedness|Company Short-Term Debts Metagenomi|Quick Liquidity metagenomi.co
- net income and valuation ratios data:
MGX - Company Profit
Basic company analysis:Metagenomi, MGX
Brand item of Metagenomi Therapeutics

For investors in the high-tech sector, Metagenomi, Inc. (MGX) is an attractive player in the capital-intensive gene editing niche. This metric measures the proportion of borrowed funds relative to equity, and analyzing the debt-to-equity ratio allows for an assessment of the company's financial stability amidst colossal expenditures on CRISPR patents and regulatory requirements, thereby minimizing default risk.

Competitors of Metagenomi, Inc. (MGX)

Debt to Equity tempus.com|Debt to Equity Ratio QGEN (Qiagen NV)|Total Debt to Capital IONS|Total Debt to Capital Repligen Inc. (RGEN)|Debt to Equity Avidity Biosciences RNA|CRSP - Total Debt to Equity Ratio|GeneDx - Total Debt to Capital|Debt to Capital Ultragenyx Pharmaceutical Inc.|BEAM (Beam Therapeutics Corp) - Total Debt to Equity Ratio|SRPT: Aggregate Debt to Capital|TWST (Twist Bioscience) - Total Debt to Capital|Total Debt to Capital 10xgenomics.com|Total Debt to Capital NTLA|Stoke Therapeutics Inc (STOK) - Debt to Capital Ratio|Total Debt to Capital BLFS (BioLife Corp)|Wave Pharma (WVE) - Debt to Capital|MAZE - Debt to Equity|SION (sionnatx.com) - Debt to Equity Ratio|Prime Medicine (PRME) - Debt to Equity|Debt to Capital Taysha Gene Therapies Inc (TSHA)|Debt to Equity uniQure Corp|Total Debt to Equity Ratio MeiraGTx Corp (MGTX)|Total Debt to Capital RGNX|Total Debt to Capital Coefficient solidbio.com|Ocugen - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio PACB|Benitec - Total Debt to Capital|Total Debt to Capital Coefficient Design Corp DSGN|Rocket Pharmaceuticals (RCKT) - Debt to Equity|Debt to Equity Ratio FDMT|LXEO (Lexeo Therapeutics Inc.) - Total Debt to Capital|Total Debt to Equity Ratio Korro Bio, Inc (KRRO)|Total Debt to Equity Ratio EDIT (Editas)|Total Debt to Capital Coefficient Silence Therapeutics Corp|Debt to Equity ProQR Therapeutics PRQR|CDXS - Total Debt to Equity Ratio|Sangamo Therapeutics, Inc. - Total Debt to Capital|Debt to Capital Ratio Nautilus Biotechnology (NAUT)|DTIL (Precision BioSciences, Inc.) - Total Debt to Equity Ratio|Debt to Equity Ratio GBIO|BOLD (Boundless Bio, Inc.) - Total Debt to Capital|Debt to Equity Ratio XCUR (Exicure Corp)|Debt to Equity Imunon, Inc. (IMNN)|phiopharma.com - Debt to Equity Ratio|Total Debt to Capital MBIO (Mustang Bio)|Total Debt to Capital TransCode Therapeutics Inc. RNAZ|BNGO - Debt to Equity|adnas.com (APDN) - Total Debt to Equity Ratio|BLUE: Total Debt to Capital|Debt to Capital ImmunoPrecise Antibodies Ltd. (IPA)|Total Debt to Equity Ratio OMGA|OMIC (Singular Genomics Corp) - Aggregate Debt to Capital|Total Debt to Capital RGLS|Total Debt to Capital syros.com (SYRS)|Total Debt to Capital TBIO (Telesis Bio)|Debt to Capital Ratio TRACON Pharmaceuticals Inc.|Unity Bio - Total Debt to Capital